Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

May 29, 2021

Study Completion Date

May 29, 2021

Conditions
Stroke, Ischemic
Interventions
DRUG

Butyphthalide combined with rtPA

Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.

DRUG

rtPA

Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines

Trial Locations (1)

Unknown

General Hospital of ShenYang Military Region, Shenyang

All Listed Sponsors
lead

Hui-Sheng Chen

OTHER

NCT03394950 - Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter